Karyopharm Therapeutics (KPTI) Misses Q1 EPS by 124c

Karyopharm Therapeutics (NASDAQ: KPTI) reported Q1 EPS of ($1.24). Revenue for the quarter came in at $35.07 million.

For earnings history and earnings-related data on Karyopharm Therapeutics (KPTI) click here.

You May Also Be Interested In

• Tesla Crash Into Texas Home Now Under Federal Safety Probe - WSJ
• Avis Budget Group reaches $650M settlement with Pentwater Capital
• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings